S
Samir N. Khleif
Researcher at Georgia Regents University
Publications - 103
Citations - 4447
Samir N. Khleif is an academic researcher from Georgia Regents University. The author has contributed to research in topics: Immunotherapy & Cancer. The author has an hindex of 34, co-authored 92 publications receiving 3782 citations. Previous affiliations of Samir N. Khleif include Regent University & Georgetown University Medical Center.
Papers
More filters
Journal ArticleDOI
Cancer classification using the Immunoscore: a worldwide task force
Jérôme Galon,Franck Pagès,Francesco M. Marincola,Francesco M. Marincola,Helen K. Angell,Helen K. Angell,Magdalena Thurin,Alessandro Lugli,Inti Zlobec,Anne Berger,Carlo Bifulco,Gerardo Botti,Fabiana Tatangelo,Cedrik M. Britten,Sebastian Kreiter,Lotfi Chouchane,Paolo Delrio,Hartmann Arndt,Martin Asslaber,Michele Maio,Giuseppe Masucci,Martin C. Mihm,Fernando Vidal-Vanaclocha,James P. Allison,Sacha Gnjatic,Leif Håkansson,Christoph Huber,Harpreet Singh-Jasuja,Christian H. Ottensmeier,Heinz Zwierzina,Luigi Laghi,Fabio Grizzi,Pamela S. Ohashi,Patricia Shaw,Blaise Clarke,Bradly G. Wouters,Yutaka Kawakami,Shoichi Hazama,Kiyotaka Okuno,Ena Wang,Jill O'Donnell-Tormey,Christine Lagorce,Graham Pawelec,Michael I. Nishimura,Robert E. Hawkins,Réjean Lapointe,Andreas Lundqvist,Samir N. Khleif,Shuji Ogino,Peter Gibbs,Paul Waring,Noriyuki Sato,Toshihiko Torigoe,Kyogo Itoh,P. Patel,Shilin N. Shukla,Richard Palmqvist,Iris D. Nagtegaal,Yili Wang,Corrado D'Arrigo,Scott Kopetz,Frank A. Sinicrope,Giorgio Trinchieri,Thomas F. Gajewski,Thomas F. Gajewski,Paolo A. Ascierto,Bernard A. Fox,Bernard A. Fox,Bernard A. Fox +68 more
TL;DR: Evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy, into traditional classification of cancer, designated TNM-I (TNM-Immune), and introduction of this parameter as a biomarker to classify cancers will facilitate clinical decision-making.
Journal ArticleDOI
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.
Vivek Verma,Vivek Verma,Rajeev K Shrimali,Rajeev K Shrimali,Shamim Ahmad,Winjie Dai,Hua Wang,Sumin Lu,Rahul Nandre,Rahul Nandre,Pankaj Gaur,Pankaj Gaur,José A. López,Moshe Sade-Feldman,Moshe Sade-Feldman,Keren Yizhak,Stacey L. Bjorgaard,Stacey L. Bjorgaard,Keith T. Flaherty,Jennifer A. Wargo,Genevieve M. Boland,Ryan J. Sullivan,Gad Getz,Gad Getz,Scott A. Hammond,Ming Tan,Jingjing Qi,Phillip Wong,Taha Merghoub,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Nir Hacohen,Nir Hacohen,John Edward Janik,John Edward Janik,Mikayel Mkrtichyan,Mikayel Mkrtichyan,Seema Gupta,Seema Gupta,Samir N. Khleif,Samir N. Khleif +41 more
TL;DR: It is demonstrated that PD-1 blockade in the context of suboptimal T cell activation engenders a state of non-responsiveness but not when there is strong stimulation by vaccination, which can enhance antitumor responses in a subset of cases.
Journal ArticleDOI
Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
Neil H. Segal,Scott J. Antonia,Julie R. Brahmer,Michele Maio,Andy Blake-Haskins,Xia Li,Jim Vasselli,Ramy Ibrahim,Jose Lutzky,Samir N. Khleif +9 more
TL;DR: In this paper, checkpoint blockade of the PD-1/PD-L1 and CTLA-4 pathways has been shown to be active in multiple tumor types, including lung cancer.
Journal ArticleDOI
Future perspectives in melanoma research
Paolo A. Ascierto,Sanjiv S. Agarwala,Gerardo Botti,Alessandra Cesano,Gennaro Ciliberto,Michael A. Davies,Sandra Demaria,Reinhard Dummer,Alexander M.M. Eggermont,Soldano Ferrone,Yang Xin Fu,Thomas F. Gajewski,Claus Garbe,Veronica Huber,Samir N. Khleif,Michael Krauthammer,Roger S. Lo,Giuseppe Masucci,Giuseppe Palmieri,Michael A. Postow,Igor Puzanov,Ann Silk,Stefani Spranger,David F. Stroncek,Ahmad A. Tarhini,Janis M. Taube,Alessandro Testori,Ena Wang,Jennifer A. Wargo,Cassian Yee,Hassane M. Zarour,Laurence Zitvogel,Bernard A. Fox,Bernard A. Fox,Nicola Mozzillo,Francesco M. Marincola,Magdalena Thurin +36 more
TL;DR: The sixth “Melanoma Bridge Meeting” took place in Naples, Italy, December 1st–4th, 2015 and focused on advances in immunotherapy and combination therapy for melanoma, with an overall emphasis on biomarkers.
Journal ArticleDOI
AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development
TL;DR: The AACR-FDA-NCI Cancer Biomarkers Collaborative stepped into the national effort to bring together disparate stakeholders to clearly delineate barriers, to develop recommendations for integrating biomarkers into the cancer drug development enterprise, and to set in motion the necessary action plans and collaborations.